Article abstract-Objectiue: To compare the side effect profile of risperidone with that of oral haloperidol in patients with no previous exposure to antipsychotic drugs (APDs). Background: Early studies suggested that the APD risperidone may have a side effect profile comparable with that of placebo. These t: -rly studies involved patients with chronic schizophrenia and a long history of APD use. Very little information is available regarding the neurologic side effects of risperidone in patients without previous APD exposure. Methods: The authors prospectively studied 350 consecutive neuroleptic-naive patients admitted to their acute-care psychiatry service; 34 of these were treated with risperidone (mean dose, 3.2 mg/d) and 212 were treated with low-dose haloperidol (mean dose 3.7 mgld). All patients were assessed on admission and twice weekly thereafter using rating scales for dystonia, parkinsonism, akathisia, and dyskinesia. Results: The incidence anll severity of dystonic reactions, akathisia, parkinsonism, and dyskinesia were comparable in the risperidone-and haloperidol-treated groups. Conclusions: The neurologic side effect profile of low-dose risperidone is comparable with that of haloperidol in patients receiving APDs for the first time. Risperidone may not be a useful alternative to typical APDs for patients with PD and psychosis.
Neuroleptic medications constitute the primary pharmacologic treatment for a wide variety of psy chiatric disorders. It has long been recognized, how ever, that these drugs are associated with neurologic side effects, including dystonia, parkinsonism, aka thisia, and tardive dyskinesia. In an effort to match the therapeutic efficacy of neuroleptics without in curring the neurologic side effects, a host of so-called atypical neuroleptics have recently been introduced. One of these, risperidone, has been reported in sev eral multicenter trials to have a side effect profile comparable with that of placebo and significantly less than that of haloperidol when used in doses of 6 mg/d or less. 1 -5 This has raised hope among neurolo gists that risperidone might be a useful agent for the treatment of patients with PO and psychosis. The early multicenter studies, however, involved hospi talized patients with chronic schizophrenia, all of whom had a history of long-term neuroleptic use. Very little information is available regarding the neurologic side effects of risperidone in patients with no previous exposure to neuroleptics.
We have compared the side effect profIle ofrisperi done with that of oral haloperidol in patients with no prior exposure to antipsychotic drugs (APOs).
Methods. Patients. Over the past 9 years, we have pro spectively studied the neurologic side effect profile of 350 consecutive neuroleptic-naive patients admitted to our acute-care psychiatric inpatient service who were subse quently treated with APDs. Our 28-bed unit is one of three university-affiliated facilities in the region to which pa tients are admitted from a central emergency service, serv ing a catchment area of approximately 500,000 people. The particular unit to which patients are admitted from the emergency service is determined by bed availability.
The only exclusion criterion for entry into the study was a history of APD exposure, as confirmed by 1) interviews with the patient and relatives; 2) review of hospital records; and 3) contact with the family physician. All pa tients signed an informed consent to be prospectively ex amined for medication side effects. The choice of APD, dosage, and use of concurrent medications were deter mined by one of three treating psychiatrists. Prophylactic medications such as benztropine were not used on a rou tine basis. Of the 350 patients, 34 were treated with ris peridone and 241 with haloperidol. For the purposes of comparison with risperidone, we included only those pa tients treated with oral haloperidol en = 212), excluding anyone who had received intramuscular injections in the emergency ward or at any time during hospitalization. The larger number of haloperidol-treated patients in the study to date reflects the later introduction of risperidone for routine clinical use in Canada.
Assessments. Before treatment, patients were exa:n ined by a psychiatrist (P.R.), a neurologist (M_M.), and a research nurse, and assessed for dystonia, parkinsonism, akathisia, and dyskinesia. A number of psychopathology scales, including the Brief Psychiatric Rating Scale fBPRS), which we report here, were also completed for the purposes of the study. Patients were then reassessed twice weekly during their acute hospitalization by the research nurse, who remained blinded to the medication regimen. Mean daily dosages of the APDs and any other psycho tropic medications used during treatment, including loraz epam, lithium, antidepressants, and benztropine, were calculated after the patient's discharge. Acute dystonia was diagnosed if the patient manifested a :~ustained muscle contraction sufficiently severe to require immediate treatment with intramuscular benztropine.
Akathisia was rated using the Barnes Akathisia Scale (BAS).6 The BAS includes four items: two reflect subjective restlessness and discomfort, one measures objective rest lessness, and one is a global impression of severity. The latter item is scored from 0 to 5 (0 = absent, 1 = question able, 2 = mild, 3 moderate, 4 = marked, and 5 = se vere). A patient was considered to have akathisia if a global impression score of 2 or more was assigned on at least one occasion during hospitalization.
Our parkinsonism scale was adapted from the motor examination subsection of the United Parkinson's Disease Rating Scale, and included the following items: facial and vocal expression; tremor; an alternate motion rate task; rigidity; posture, gait, and arIDswing; and writing. The Statistical analyses. Categorical variables were ana lyzed using the chi-square test and continuous variables were analyzed using the two-tailed Student's t-test. The level of statistical significance was set at p < 0.05.
Results. Table 1 shows the comparative demographic and clinical profiles of patients treated with either risperi done or haloperidol. There were no significant differences between the two groups with respect to age, sex, diagnostic profile, mean BPRS score before treatment or at discharge, average daily APD dosage, duration of APD use, or length of admission. There was a significantly greater use of ad junctive selective serotonin reuptake inhibitor (SSRD med-Discussion. We found a comparable incidence of neurologic side effects in acutely ill inpatients treated with either low-dose risperidone or low-dose haloperidoL This similarity in side effect profile sug gests that previous reports of negligible side effects in risperidone-treated patients with chronic schizo phrenia may not be generalizable to other patient groups. These early multicenter trials using risperi done involved patients with chronic, treatment resistant schizophrenia,1-5 most of whom had been off neuroleptics for less than 1 week before being ran domized to either risperidone or haloperidol. Subse quent assessments over the 7-to 8-week duration of those studies would have been contaminated by ei ther th('; vngoing effects or the withdrawal effects of the previously prescribed APD. The washout period of less than 1 week before randomization that has characterized most studies comparing risperidone with typical neuroleptics is problematic, given that neuroleptics are known to produce brain change; that persist long after the drug has been discontinued. 9--11 Our findings are consonant with emerging evi dence that the incidence of neurologic side effects in patients treated with risperidone may be higher than has previously been reported. 12 . 16 A comparative prevalence study of extrapyramidal side effects (EPS) in patients on stable dosages of clozapine, ri~ . peridone, or conventional antipsychotics found no significant differences between risperidone and con ventional antipsychotics. 15 A recent study12 compar ing risperidone to haloperidol plus amitriptyline in the treatment of patients with psychosis and mood disturbance found the incidence of EPS to be 37.1% and 31.1%, respectively, in the two groups. In other prospective trials of low-dose risperidone in elderly patients with dementia, EPS were found in 50% to 53%. 13, 14 To our knowledge, the only other prospective study of risperidone in a neuroleptic-naive popula tion involved 22 predominantly male inpatients with schizophrenia who were assessed for side effects before treatment and just before discharge approxi mately 7 weeks later, with no intervening assesp ment. 17 The investigators found no "clinically significant" EPS for patients taking risperidone 2 to 4 mg/d and "mild" EPS in 32% of those taking 5 to 8 mg/d. The lack of regular assessments may have ac counted for the low rate of EPS that was observed. Such an approach would almost certainly result in underestimation of the actual frequency of side ef fects, which may vary from one day to another de pending on changes in antipsychotic dosages, use u:' other medications, time of day the assessment is car ried out, and factors such as stress, fatigue, or sub stance abuse. 18 A somewhat surprising finding in the current study was the higher rate of akathisia, albeit nonsig nificant, in risperidone-treated patients. This may be related to the more frequent use of SSRIs, which themselves have been associated with a broad rang' ication in the risperidone-treated patients (p < 0.03), but concurrent use of lorazepam, lithium, benztropine, and tri cyclic antidepressants was comparable in the two groups. Figure 1 shows the comparative incidence of dystonic reactions, akathisia, parkinsonism, and dyskinesia for the risperidone and haloperidol groups during hospitalization. The incidence of acute dystonia, parkinsonism, and akathi sia was high for both groups, with no significant differ ences between them for any of the side effects. There was a nonsignificant trend toward increased dystonia in haloperidol-treated patients and toward increased akathi sia in the risperidone group. The comparative severity rat , ings for akathisia and parkinsonism in the risperidone and haloperidol treated patients are shown in table 2. 5 (14) 8 (24) 4 (12) 14 (41) 13 (38) 7 (21) 0 (0) 126 (61)* 42 (20) 29 (14) 11 (5) 95 (48)t
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t Excluding 10 patients with pretreatment evidence of parkin sonism.
cf EPS, particularly akathisia/ 9 -21 perhaps reflecting Lle inhibitory effect of serotonin on ventral tegmen tal and substantia nigra neurons. 22 The side effect profiles observed in this study oc curred on a regimen of low-dose medication. There has been an effort in recent years to reduce APD dosage in the treatment of psychosis. This recom mendation has been based on the assumption that lower dosages would result in a more benign side e;fect profile. Our data suggest that this assumption may not be justified: the incidence of neurologic side effects in our patients was over 50% despite mean daily dosages of 3.2 mg in the risperidone group and 3.7 mg in haloperidol-treated patients. This indicates that dosage reduction alone will not be sufficient to obviate this troublesome effect of APDs.
These findings are of considerable relevance to nmrologists who are treating patients with PD and psychosis. A well recognized problem of dopaminer gic agents is their propensity to induce or exacerbate psychotic symptoms. Typical neuroleptic agents may treat the psychosis but worsen the parkinsonism. The early reports that risperidone may be able to treat psychosis without producing parkinsonism raised hopes that it may be a useful agent in the treatment of pRtients with PD and psychosis. Our findings, and those of several other recent studies, [23] [24] [25] indicate that the side effect profile of risperidone may be very simi lar to that of typical APDs, and that risperidone may therefore not be a useful alternative in the treatment of patients with PD and psychosis.
